What is it about?
Review of studies demonstrating the major involvement of bloodborne fibrocytes in the amplification of immune responses and in the progression of structural changes in asthma. Critical assessment of the different methods proposed for the evaluation of blood fibrocytes count as a prognostic biomarker in asthma.
Featured Image
Why is it important?
Description of the main molecular mechanisms and signaling pathways through which fibrocytes are mobilized and participate in the remodeling of the bronchial structure in inadequately treated asthma with persisting inflammation. Discussion of the potential advantages of using blood fibrocytes count as a biomarker to monitor the level of asthma control and to recognize patients at high risk of future adverse outcomes. Comparison of the reliability and clinical applicability of published assays.
Perspectives
Validation of the use of blood fibrocytes count as biomarker of asthma control and disease progression. Integration of agents targeting fibrocytes trafficking and activation into the management strategy for patients with asthma resistant to currently available drugs because this approach may greatly reduce the future risk of acute exacerbations and adverse outcomes.
Dr. Sabrina Mattoli
Avail Biomedical Research Institute
Read the Original
This page is a summary of: Pathogenetic and prognostic roles of bloodborne fibrocytes in asthma, Journal of Zhejiang University SCIENCE B, August 2015, Journal of Zhejiang University SCIENCE,
DOI: 10.1631/jzus.b1500129.
You can read the full text:
Contributors
The following have contributed to this page
